First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05601726|
Recruitment Status : Recruiting
First Posted : November 1, 2022
Last Update Posted : November 23, 2022
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia, Adult Myelodysplastic Syndromes||Drug: ABD-3001||Phase 1|
This FIH study combines, in patients with primary refractory or relapsed AML patients and in patients with high risk MDS a Single Ascending Dose (SAD) part (Part A) and a Multiple Ascending Dose (MAD) part followed by a "Regimen optimization" (part B).
The objective of the SAD phase is to explore a wide range of dose administered as a single and fixed 4-hours intravenous infusion in order to select a dose and a dosing frequency (determined using pharmacokinetic and pharmacodynamics parameters).
The objective of the MAD is to elucidate the pharmacokinetic (PK) and pharmacodynamics (PD) of multiple doses of ABD-3001. The dose levels and dosing intervals (i.e., time between consecutive doses) will be selected as those that are predicted to be safe from the SAD. Dose levels and dosing frequency will be derived from data obtained during the SAD.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design. It will consist in a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part followed by a "Regimen optimization" part with an extension cohort.|
|Masking:||None (Open Label)|
|Official Title:||First-In-Human, Open Label, Dose Escalation Study to Evaluate Safety, PK and PD of ABD-3001 as Monotherapy in Relapsed/Refractory Acute Myeloid Leukemia or High/Very-high Risk Myelodysplastic Syndromes Patients, Ineligible for Intensive or New Generation Targeted Therapy.|
|Actual Study Start Date :||November 8, 2022|
|Estimated Primary Completion Date :||October 2024|
|Estimated Study Completion Date :||December 2024|
Experimental: Single Administration Dose (SAD) of ABD-3001
Dose escalation of 6 doses level using a 3+3 design.
Each patient will receive a single and fixed 4 hours-intravenous infusion dose of ABD-3001. The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m².
Other Name: DIMATE
Experimental: Multiple Administration Dose (MAD) of ABD-3001
Dose escalation of 3 doses level for a full cycle of treatment (28 days).
Based on PK data gathered during the SAD, a dose regimen optimization will be done using population Pharmacokinetic modelling in order to set the optimal frequency of infusion per week to achieve sustained exposition throughout treatment period. Based on this analysis, the Sponsor will, in accordance with the Safety review Committee, define the occurrence of infusion to 1, 2 or 3 times per week, during 4 weeks (28 days ± 3 days).
Number of infusions given per week and dose increase between each dose will be set so that, whatever the initial dose used in the MAD part, total dose increase will never get above the MTD determined in the SAD part or a dose defined by the SRC, if no MTD is determined during the SAD part.
Other Name: DIMATE
- Estimation of the Maximum Tolerated Dose (MTD) [ Time Frame: 7 days for SAD part up to 2 months for MAD part. ]The primary endpoint is to assess the MTD by evaluation of incidence of patients who experienced Dose Limiting Toxicities (DLTs) assessed according to CTCAE v5.0.
- Recommendation of the dose for the Phase 2 (RP2D). [ Time Frame: 2 months for MAD part. ]The recommendation for the Phase 2 dose will be determined using MTD, cumulative safety and signs of anti-leukemic activity, pharmacokinetic and pharmacodynamic characteristics.
- Adverse events [ Time Frame: 7 days for SAD part up to 2 months for MAD part. ]Incidence of Adverse Events as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0 Nov. 27, 2017), timing, seriousness, and relationship to ABD-3001 either observed by the investigator during physical examination, or reported spontaneously by the patient.
- PK parameters assessment (Cmax) [ Time Frame: 7 days for SAD part up to 2 months for MAD part. ]Evaluation of maximum concentration (Cmax) of ABD-3001.
- PK parameters assessment (AUC) [ Time Frame: 7 days for SAD part up to 2 months for MAD part. ]Evaluation of Area Under the Curve (AUC) of ABD-3001.
- PK parameters assessment (Tmax) [ Time Frame: 7 days for SAD part up to 2 months for MAD part. ]Evaluation of time to maximum concentration (Tmax) of ABD-3001.
- PK parameters assessment (T1/2) [ Time Frame: 7 days for SAD part up to 2 months for MAD part. ]Evaluation of elimination half-life of ABD-3001.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05601726
|Contact: Guillaume MARTIN||+33 (4) 82 53 89 firstname.lastname@example.org|
|Contact: Laurent BASSET||+33 (0)4 28 29 46 email@example.com|
|Hôpital de la Timone||Recruiting|
|Marseille, France, 13005|
|Contact: Régis COSTELLO firstname.lastname@example.org|
|Hôpital Saint-Louis||Not yet recruiting|
|Paris, France, 75475|
|Contact: Lina BENAJIBA email@example.com|
|Centre Hospitalier Lyon Sud||Not yet recruiting|
|Pierre-Bénite, France, 69495|
|Contact: Maël HEIBLIG firstname.lastname@example.org|
|Study Director:||Laurent BASSET||Advanced BioDesign|